Investors seeking diversified exposure to U.S. healthcare often narrow their choices to two dominant, directly competing funds: the iShares U.S. Healthcare ETF (IYH) and the Health Care Select Sector SPDR Fund (XLV). Both are passively managed vehicles offering broad, market-capitalization-weighted access to pharmaceuticals, biotechnology, medical devices, and managed care, and they share many of the same top holdings. Because their exposure profiles overlap so heavily, the practical decision between them tends to hinge on structural factors rather than sector view: cost, breadth, and liquidity. This ETF comparison examines how these funds differ beneath the surface and how relative positioning may matter in the current market environment.
The iShares U.S. Healthcare ETF (IYH), issued by BlackRock, seeks to track the Russell 1000 Health Care RIC 22.5/45 Capped Index, which applies Regulated Investment Company (RIC) diversification caps to the healthcare segment of the U.S. equity market. The fund typically holds around 104 securities, giving it a somewhat broader mid- and small-cap footprint than sector funds built strictly from S&P 500 constituents. Its industry mix leans heavily into pharmaceuticals (roughly 38%), biotechnology (about 21%), and health care equipment (about 15%), with managed health care and life sciences tools contributing smaller slices. Top holdings include LLY, JNJ, ABBV, MRK, and UNH. The fund carries an expense ratio of 0.38% and is classified as non-diversified, with a three-year equity beta below 0.55 reflecting healthcare's traditionally defensive character.
The Health Care Select Sector SPDR Fund (XLV), managed by State Street Global Advisors, tracks the Health Care Select Sector Index, which comprises healthcare stocks drawn from the S&P 500. With roughly 63 holdings, it offers a more concentrated, large-cap-oriented portfolio, though its top weights closely mirror those of IYH. Leading positions include LLY, JNJ, ABBV, UNH, and MRK, with the top ten names representing nearly 60% of assets. Its expense ratio is just 0.08%, among the lowest in the healthcare segment. As the largest healthcare sector ETF, with AUM in the tens of billions of dollars, XLV offers exceptional liquidity and tight bid-ask spreads, and it employs a full-replication strategy against its index.
Both funds are shaped by the same macro and regulatory currents. GLP-1 weight-loss and diabetes therapies continue to drive outsized returns from dominant pharmaceutical names, lifting the concentration in companies such as LLY. Meanwhile, interest-rate expectations, Medicare and Medicaid policy debates, drug-pricing legislation, and antitrust scrutiny of insurers and pharmacy benefit managers have kept volatility elevated across managed care and providers. A resilient innovation pipeline in biotechnology and medical devices offers structural growth support, while defensive cash flows have historically made healthcare a favored allocation during periods of economic uncertainty. The sector's risks center on regulatory reform, patent expirations, and the elevated valuations of high-growth leaders, all of which influence both ETFs almost identically.
Over recent weeks and months, IYH and XLV have moved largely in tandem, reflecting their shared mega-cap leadership. XLV's slightly higher concentration in the largest names has at times amplified momentum during rallies in pharmaceutical leaders, while IYH's broader roster, including more mid-cap biotechnology and equipment names, has provided marginally greater diversification and muted the drag of any single weak performer. From a relative positioning standpoint, XLV's near-identical exposure, delivered at a fraction of the cost and with superior liquidity, has allowed it to compound returns more efficiently across recent market cycles. Both funds retain low equity betas relative to the broad market, underscoring their role as defensive sector allocations.
Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to surface trade ideas, trending tickers, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to refine your own healthcare or sector-level watchlists.
On a structural basis, Tickeron's AI would likely favor XLV over IYH. Both funds deliver nearly identical sector exposure and share the same dominant top holdings, so differentiation rests on cost efficiency, liquidity, and trend consistency. XLV's 0.08% expense ratio versus IYH's 0.38% creates a compounding cost advantage, while its larger AUM and tighter spreads improve execution for institutional and retail traders alike. The AI would weigh this favorable risk-adjusted profile, consistent sector momentum, and comparable diversification as the more efficient route to broad healthcare exposure, assigning a probabilistic preference to XLV.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IYH moved below its 50-day moving average on November 20, 2026 date and that indicates a change from an upward trend to a downward trend. In 31 of 39 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 79%.
The 10-day RSI Indicator for IYH moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 25 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 76%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IYH as a result. In 65 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for IYH turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 35 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IYH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for IYH crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
Following a +0.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where IYH advanced for three days, in 251 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
IYH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 204 of 254 cases where IYH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where XLV declined for three days, in 250 of 308 cases, the price declined further within the following month. The odds of a continued downward trend are 81%.
The 10-day RSI Indicator for XLV moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 27 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 73%.
The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on XLV as a result. In 72 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for XLV turned negative on November 16, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 38 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for XLV crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 77%.
Following a +0.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where XLV advanced for three days, in 264 of 325 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
XLV may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 225 of 273 cases where XLV Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 82%.
| IYH | XLV | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 76% | 3 days ago 73% |
| Stochastic ODDS (%) | 3 days ago 74% | 3 days ago 84% |
| Momentum ODDS (%) | 3 days ago 72% | 3 days ago 73% |
| MACD ODDS (%) | 3 days ago 71% | 3 days ago 78% |
| TrendWeek ODDS (%) | 3 days ago 78% | 3 days ago 78% |
| TrendMonth ODDS (%) | 3 days ago 82% | 3 days ago 81% |
| Advances ODDS (%) | 12 days ago 80% | 12 days ago 81% |
| Declines ODDS (%) | 3 days ago 79% | 3 days ago 81% |
| BollingerBands ODDS (%) | 3 days ago 68% | 3 days ago 76% |
| Aroon ODDS (%) | 3 days ago 80% | 3 days ago 82% |
A.I.dvisor indicates that over the last year, IYH has been closely correlated with LLY. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if IYH jumps, then LLY could also see price increases.
A.I.dvisor indicates that over the last year, XLV has been closely correlated with LLY. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if XLV jumps, then LLY could also see price increases.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SDOW | 30.46 | 1.64 | +5.69% |
| ProShares UltraPro Short Dow30 (SDOW) | |||
| PMOC | 26.12 | -0.17 | -0.63% |
| PGIM S&P 500 Max Buffer ETF - October (PMOC) | |||
| DECU | 27.38 | -0.43 | -1.55% |
| AllianzIM U.S. Equity Buffer15 Uncapped Dec ETF (DECU) | |||
| BINV | 43.19 | -0.68 | -1.56% |
| Brandes International ETF (BINV) | |||
| JGLO | 65.26 | -2.48 | -3.66% |
| JPMorgan Global Select Equity ETF Global Select Equity ETF (JGLO) | |||